

Drug Utilization Review Board
(DUR Board)
Meeting – February 11, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Meece, Vice-Chair:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Meece, Vice-Chair:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. Meece, Vice-Chair:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. January 14, 2009 DUR Minutes – Vote
 - B. January 15, 2009 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Meece, Vice-Chair:

- 4. Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for November 2008
 - B. Retrospective Drug Utilization Review Responses for September 2008
 - C. Medication Coverage Activity Audit for January 2009
 - D. Help Desk Activity Audit for January 2009

Items to be presented by Dr. Le, Dr. Meece, Vice-Chair:

- 5. 30 Day Notice to Prior Authorize Advair[®] and Symbicort[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Meece, Vice-Chair:

- 6. Action Item – Annual Review of Fibric Acid Derivative PBPA Category and 30 Day Notice to Prior Authorize Fenoglide[™], Lipofen[®], and Trilipix[™] – See Appendix D.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Robinson, Dr. Meece, Vice-Chair:

7. **Action Item – Annual Review of Nasal Allergy PBPA Category and 30 Day Notice to Prior Authorize Astepro™ – See Appendix E.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. Keast, Dr. Meece, Vice-Chair:

8. **Action Item – Annual Review of Ocular Allergy PBPA Category – See Appendix F.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Moore, Dr. Meece, Vice-Chair:

9. **Utilization Review of Anti-Ulcer / GERD Medication for Children – See Appendix G.**
 - A. Product Overview
 - B. Utilization Review

Items to be presented by Dr. Keast, Dr. Meece, Vice-Chair:

10. **Hydrocodone Product Evaluation – See Appendix H.**
 - A. Hydrocodone Utilization Review
 - B. Carisoprodol Utilization Review
 - C. Current Hydrocodone Restrictions
 - D. COP Recommendations

Items to be presented by Dr. Graham, Dr. Meece, Vice-Chair:

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
 - A. Annual Reviews
 - B. Utilization Review of Anti-emetics
 - C. Utilization Review of Anti-migraine products
 - D. New Product Reviews
13. **Adjournment**